Inventor · disambiguated record
Matthew Onsum
Also filed as: ONSUM MATTHEW · ONSUM MATTHEW D · ONSUM MATTHEW DAVID
15 granted patents·10 pending applications·116 citations·filing 2009–2024
94Inventor score
Files withSILVER CREEK PHARMACEUTICALS INC13MERRIMACK PHARMACEUTICALS INC7NIELSEN ULRIK2GARCIA GABRIELA1ONSUM MATTHEW DAVID1
Top patents by PatentIndex Score
25 records- 0195US9238080B2Bi-specific fusion proteinsNIELSEN ULRIK·Filed 2011·Granted Jan 19, 2016·29 cites·21 claims
- 0294US10988547B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2019·Granted Apr 27, 2021·6 cites·7 claims
- 0394US9718892B2Method of treating myocardial infarction by administering a bi-specific fusion proteinMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Aug 1, 2017·12 cites·10 claims
- 0494US8691771B2Bi-specific fusion proteins for tissue repairNIELSEN ULRIK·Filed 2011·Granted Apr 8, 2014·21 cites·9 claims
- 0593US10858450B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2018·Granted Dec 8, 2020·6 cites·7 claims
- 0693US10407512B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·9 cites·8 claims
- 0791US9982060B2Bi-specific fusion proteinsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted May 29, 2018·9 cites·15 claims
- 0890US11814443B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Granted Nov 14, 2023·1 cites·20 claims
- 0990US11155593B2Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5SILVER CREEK PHARMACEUTICALS INC·Filed 2020·Granted Oct 26, 2021·3 cites·12 claims
- 1089US2024101713A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1188US11673970B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2020·Granted Jun 13, 2023·1 cites·7 claims
- 1287US8623592B2Methods and systems for predicting response of cells to a therapeutic agentSCHOEBERL BIRGIT·Filed 2009·Granted Jan 7, 2014·9 cites·11 claims
- 1387US2023322951A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1486US10040840B2Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissueSILVER CREEK PHARMACEUTICALS INC·Filed 2016·Granted Aug 7, 2018·6 cites·20 claims
- 1586US2025145682A1Compositions and methods of treating tissue damageSILVER CREEK PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1684US10633425B2Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5SILVER CREEK PHARMACEUTICALS INC·Filed 2018·Granted Apr 28, 2020·4 cites·6 claims
- 1778US12122819B2Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variantSILVER CREEK PHARMACEUTICALS INC·Filed 2022·Granted Oct 22, 2024·0 cites·14 claims
- 1876US11879002B2Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereofSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Granted Jan 23, 2024·0 cites·19 claims
- 1967US2014127238A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2058US2017307631A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2157US2011027291A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 2252US2015111217A1Marker quantitation in single cells in tissue sectionsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2352US2017082630A1Marker quantitation in single cells in tissue sectionsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2439US2014234317A1Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agentsONSUM MATTHEW DAVID·Filed 2012·Application pending·0 cites
- 2538US2015231238A1Overcoming resistance to erbb pathway inhibitorsGARCIA GABRIELA·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew Onsum files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →